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Abstract: Lung cancer is the leading worldwide source of cancer-
related death. It is acknowledged that prognosis and treatment
outcomes in lung cancer might be improved by increasing the
effectiveness of early-stage diagnosis. Several recently published
studies have produced intriguing results regarding the detection of
biomarkers in tumor samples, but also in easily accessible specimens
such as sputum, plasma, and exhaled breath condensate. This review
presents advances in genetic diagnostics of lung cancer, with par-
ticular reference to the clinical usefulness of individual biomarkers,
specimens, and methods. The adequacy of their sensitivity and speci-
ficity for cancer screening and early detection is discussed in detail.
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Lung cancer is currently regarded as one of the key epide-miological issues worldwide, with 1,200,000 new cases
per year and only 10% (range, 5.5%–14.3%) of patients
surviving their malignancy.1,2 Although the prognosis in lung
cancer is strongly correlated with disease stage at the time of
diagnosis, no easily applicable methods exist for screening or
early detection. It is hoped that molecular biology will even-
tually provide useful diagnostic biomarkers and tests, allow-
ing reliable preselection of patients before, or in combination,
with modern diagnostic imaging procedures such as fluores-
cence bronchoscopy, low-dose computed tomography (CT),
and integrated positron emission tomography/CT. Molecular
biology techniques might effectively estimate the expression
of particular appointed genes not only in tumor cells, but also
in other materials like sputum, bronchoalveolar lavage
(BAL), and serum/plasma (Table 1). The efficiency of bi-
omarker application to lung cancer diagnosis depends both on
the validity of the selected marker (its sensitivity and speci-
ficity) and on the choice of accessible biological material.3
TISSUE SPECIMENS FOR MOLECULAR TESTING
Biomarkers appropriate for a screening program should
demonstrate a major difference between the tumor and nor-
mal tissue, correlate with cancer progression, and require no
or a minimally invasive sampling technique with a low cost
and high efficacy.4 Several materials have been tested in the
search for a useful and reliable source of biomarkers for
screening and early diagnosis of lung cancer. Although some
studies have produced promising data, no definite applica-
tions have yet been introduced into the clinical routine.
SPUTUM
It has been repeatedly demonstrated that cytologic eval-
uation of sputum samples due to its low sensitivity is an
inadequate method for lung cancer screening and early diag-
nosis. Therefore, sputum examination serves as a good re-
minder of the advantages that biomarker analysis offers,
especially in combination with other diagnostic methods.
Nuclear image analysis based on stoichiometric DNA-
specific nuclear staining is currently perceived as one of the
most promising novel biomolecular techniques. Implementa-
tion of the Feulgen-thionine reaction results in a linear rela-
tionship between the staining intensity and DNA quantity in
a sample.5 Palcic et al.6 analyzed malignancy-associated
changes in normal (nonmalignant) sputum cells by means of
semiquantitative nuclear image analysis and demonstrated
45% sensitivity and 90% specificity in stage I lung cancer. In
comparison, an evaluation performed using the standard Sac-
comano cytology method showed 14% sensitivity and 99%
specificity. Developing an automated quantitative modifica-
tion of this method has resulted in significantly improved
sensitivity (75%–82%) and specificity (90%) of sputum cell
evaluation.7 Nuclear image analysis appears highly promising
for improving or refining diagnosis beyond the use of a
conventional sputum cytology examination.
Moreover, McWilliams et al.8 reported that an auto-
mated quantitative sputum nuclear image analysis combined
with spiral CT scanning in a routine lung cancer screening of
a high-risk population of heavy smokers resulted in an addi-
tional benefit (detection rate of 2.1%) over high-resolution
CT alone (detection rate of 1.8%). Furthermore, multiple
screening, including autofluorescence bronchoscopy, further
increased the overall detection rate to 3.1%. The results of
that study also imply the potential positive economic and
psychological effect of biomarker implementation. Prelimi-
nary molecular screening prior to the execution of invasive or
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radiographic diagnostic procedures should allow easier and
less expensive positive identification of lung cancer patients.
In the McWilliams et al.8 study, none of the patients nega-
tively verified by automated quantitative sputum nuclear
image analysis were diagnosed with lung cancer.
Several other molecular techniques might prove useful
for routine early lung cancer detection. Overexpression of
heterogeneous nuclear ribonucleoproteins (hnRNPs) A2/B1
and B1 has shown promise for early detection in sputum.
Tockman et al.9 demonstrated that hnRNP A2/B1 immuno-
staining of archived preneoplastic sputum specimens detected
preclinical lung cancer threefold more accurately than stan-
dard cytomorphology. Sputum hnRNP A2/B1 overexpression
showed satisfactory sensitivity (82%) and specificity (65%),
with a positive predictive value of 69% and negative predic-
tive value of 20%. However, Sueoka et al.10 noted that
although 100% of stage I lung cancer tissue examined dem-
onstrated positive staining with anti-hnRNP B1 antibody,
only three of 12 sputum samples were positive. Apparently,
although the reactivity of hnRNP B1 antibody was classified
as strong in the sputum of lung cancer patients, its affinity
might not be sufficiently high for large-scale application, and
it is in need of further refinement.
The applicability of multitarget fluorescence in situ
hybridization (FISH) to sputum analysis has also been re-
cently assessed. FISH is the chromosomal instability evalu-
ation technique that allows the simultaneous screening and
assessment of changes in several distinct DNA sequences.
Evaluation of the sputum specimens, obtained at least 12
months before lung cancer diagnosis, with the probe set for
analysis of 5p15, 6p11-q11, 7p12, and 8q24, revealed aneu-
somy in 41% of the subjects (cutoff of two or more abnormal
cells).11 However, combining FISH with cytology improved
the sensitivity to 83%,12 with a concomitant decrease in the
specificity from 94% to 80% (similar to cytology alone).
However, Kettunen et al.13 demonstrated that FISH sensitiv-
ity (50%) did not significantly exceed the sensitivity of
sputum cytology (44%) in lung cancer diagnosis. Likewise,
FISH analysis of 5p15, 6p11-q11, 7p12, and 8q24 sequences
was not able to distinguish heavy tobacco smokers and
asbestos-exposed workers from healthy nonsmokers (20%,
12%, and 27% positive individuals, respectively; cutoff of
three or more abnormal cells). Thus, additional studies are
needed to identify other hybridization targets (chromosomal
loci) for FISH probes that would prove more useful for lung
cancer risk assessment and early detection.
The methylation-specific polymerase chain reaction
(MSP) is an extremely sensitive technique for assessing the
methylation status of DNA promoter regions. Aberrant meth-
ylation of p16 and other tumor-related genes has been repeat-
edly detected in sputum DNA and has been shown to be an
early event in lung cancer.14 Therefore, several biomarkers
potentially useful for early diagnosis have been evaluated in
sputum using the MSP method. Palmisano et al.15 detected
aberrant methylation of p16 and/or MGMT promoters in
sputum DNA of all 10 patients with squamous cell carcinoma
(SCC) up to 3 years before clinical diagnosis, whereas only
one patient showed positive sputum cytology. Concordance
between p16 and MGMT methylation in the primary SCC and
paired sputum samples was 90% and 78%, respectively, for
each gene. Furthermore, a comparative study on plasma and
sputum samples from subjects grouped with respect to lung
cancer risk revealed that methylation of three genes (p16,
MGMT, and RASSF1A) was generally more common in
sputum than in plasma. Similarly, the prevalence for
RASSF1A and MGMT methylation was significantly greater
in sputum than in plasma from lung cancer survivors (25%
versus 7% and 36% versus 11%, respectively), whereas p16
methylation occurred more frequently in sputum than in
plasma from smokers (25% versus 13%).16 Meanwhile, Cir-
incione et al.17 failed to identify early lung cancer patients
with tumors detected by spiral CT using a panel of methyl-
ated RAR2, p16, and RASSF1A markers in DNA from
sputum. Methylation of both p16 and RASSF1A genes was
detected in the sputum of only one of 18 (5%) patients with
paired tumor samples, and in one of 112 (0.9%) and 20 of 112
(17.8%) sputum samples, respectively, from cancer-free
smokers. Moreover, RAR2 methylation was revealed in the
sputum of CT-detected patients (8/18, 44.4%) and heavy
smokers without cancer (58/112, 51.7%), suggesting that it is
an exposure-related rather than tumor-specific marker. In
contrast, a differently designed marker system revealed quite
promising sensitivity in a methylation study on sputum sam-
ples from 22 patients with resected non-small cell lung cancer
(NSCLC). Abnormal methylation in the cytologically nega-
tive sputum samples was displayed by 64% of HOX A9, 50%
of MAGE A1, 41% of MAGE B2, and 27% of p16 promot-
ers.18 Furthermore, 95.5% of the negative sputum samples
from NSCLC patients showed abnormal methylation in at
least one gene tested. However, the lack of a control group is
a serious limitation for this study and prevents any prospec-
tive conclusions being drawn. Consequently, the diagnostic
utility of the proposed marker set needs further confirmation.
Note that several inaccuracies in the MSP procedure might
generate false-positive results, and thus, a crossover study
comparing different technical approaches for methylation
detection is necessary before its further diagnostic implemen-
tation.
Although novel technologies create new challenging and
promising perspectives, some very practical aspects should not
be forgotten. The low yield of sputum cytology is a common
problem, its induction is relatively time-consuming (15–30 min-
utes), and specific conditions for sample storage and transpor-
tation must be guaranteed. All these might affect the repro-
ducibility of sputum analysis results and its usefulness for
screening and early diagnostic purposes.
BAL
BAL is conducted by reaspirating the sterile saline
solution infused into the airways of a patient undergoing
bronchoscopy. Thus, BAL potentially provides samples con-
taining a deeper epithelial component than that found in
sputum samples.
As early as 1999, Ahrendt et al.19 implemented PCR-
based techniques to assess molecular markers in the BAL-
derived cellular material from 50 patients with resectable
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NSCLC. However, the frequency of most typical alterations
in the p53 and K-ras gene expression or p16 promoter
methylation was significantly lower in BAL than in tumor
samples: 53 versus 100% for all examined markers, 39 versus
56% for the p53 gene, 27 versus 33% for the K-ras gene, and
17 versus 63% for p16 methylation. Similar results have been
reported by Ferretti et al.20 who applied a novel PCR-
denaturant gradient gel electrophoresis method. Calculated
concordance between tumor and paired BAL samples in that
study was 46.6% and 43% for TP53 and K-ras, respectively,
demonstrating an overall low sensitivity. Recent reports con-
cerning the use of real-time PCR for biomarker analysis in
BAL samples have been slightly more reassuring.21 Modified
expression of the APC, RASSF1A, MGMT, and GSTP1 genes,
as well as the CDH1 methylation observed in NSCLC tumor
cells was demonstrated in parallel in approximately 68% of
BAL material (at least one gene).
Note, however, that BAL has repeatedly been shown to
have a significantly higher diagnostic value to that of sputum-
derived material. Fielding et al.22 confirmed a 96% sensitivity
and 82% specificity of hnRNP A2/B1 overexpression in BAL
specimens from patients with premalignant and malignant
lung lesions. Importantly, hnRNP overexpression was shown
in 41 of 80 specimens reported as negative in routine cyto-
logic examinations. Similarly, Chan et al.23 directly compared
the sensitivity of MSP versus conventional cytology in de-
tecting cancer cells in BAL samples. MSP biomarkers were
positive in 35 of 41 patients with negative cytology and
histologically confirmed malignant pulmonary lesions.
In summary, according to available data, molecular
approaches to biomarker assessment in BAL-derived material
are characterized by inadequate sensitivity, even if their
specificity seems acceptable. This may be due to both an
insufficient level of cellular tumor DNA in BAL and exces-
sive contamination with normal DNA.21 Indeed, cancer cells
in BAL fluid are usually mixed with a large number of normal
cells, such as alveolar macrophages, white blood cells, and
normal epithelial cells.20
Therefore, the detection and analysis of DNA in cell-
free lavage supernatant appear to be an interesting alternative.
Carstensen et al.24 found microsatellite alterations (MAs) in
the intact cell-free DNA from BAL fluids in 47% of the lung
cancer patients evaluated. The majority of DNA alterations
found in the cell-free lavage supernatants was not detected in
lavage cells, once again demonstrating the low accuracy of
cytologic examination. Recently, extracellular mRNA isolated
from cell-free lavage supernatant was also analyzed, both qual-
itatively and quantitatively, showing interesting results.25
Finally, the technical obstacles that limit the clinical
applicability of BAL should be mentioned, with the require-
ment for bronchoscopy being the most important. In addition
to its invasiveness, it cannot be repeated frequently, espe-
cially in high-risk patients. Additionally, genetic analysis of
BAL might not be particularly helpful in detecting peripheral
cancer. Thus, the more diagnostically convenient materials
such as sputum, blood, and exhaled breath condensate (EBC)
should be taken into account as first-line materials for the
validation of relevant markers.
EBC
EBC is a reliable source of proteins, nucleotides, lipids,
oxidants, and human DNA derived from the fluid lining the
respiratory tract.26 Genetic analysis has shown several TP53
mutations (exons 5–8) in EBC from four of 11 NSCLC
patients (36%), but not from healthy nonsmoking subjects.27
Carpagnano et al.28 analyzed EBC-derived DNA samples
from 30 NSCLC patients and 20 healthy volunteers for the
presence of MAs on chromosome locus 3p. The number of
MAs (either microsatellite instability or loss of heterozygos-
ity) in EBC DNA was significantly higher in NSCLC patients
than in healthy controls with a comparable history of smok-
ing. Interestingly, the most frequently altered 3p microsatel-
lite in EBC DNA was D3S1300 located in the FHIT gene,
thus supporting an association between FHIT inactivation and
carcinogenesis.
Regardless of the above-mentioned findings, several
advantages of EBC essential for its potential application in
lung cancer diagnosis should be noted. EBC collection is an
easy, repeatable, and totally noninvasive procedure, unrelated
in any way to patient airway function. Likewise, the required
volume of diagnostic material can be obtained in a very
economical manner, without the need for a highly specialized
hospital environment. However, standard procedures con-
cerning sample collection and results presentation need to be
established.26
Further research will show whether genomic and pro-
teomic analysis of EBC has an impact on lung cancer detec-
tion. Nevertheless, it seems reasonable to pursue this approach
and expand the biomarkers panel with (proto)oncogenes or
suppressor genes, as well as protein factors.
PERIPHERAL BLOOD (SERUM/PLASMA)
Although BAL material examination remains disap-
pointing and EBC applicability needs further evaluation,
peripheral blood assessment as a reservoir of lung cancer
biomarkers has proven surprisingly efficient.29 From a tech-
nical point of view, blood seems an ideal candidate material
for screening and early diagnostic programs. It is easily and
cheaply accessible, and in district outpatient clinics outside
large hospital centers, no need exists for additional personnel
training to provide proper sampling. Therefore, extensive
research projects are currently being conducted to evaluate in
detail the diagnostic value of multiple biomarkers measured
in the peripheral blood. Data from the most representative
studies on serum/plasma genetic markers detected in the early
lung cancer are summarized in Table 2.
Nanogram amounts of free DNA exist in the serum of
healthy subjects, as well as in patients with chronic inflam-
matory and autoimmune diseases.30 Nevertheless, free serum
DNA concentration in lung cancer patients is usually several
times higher, most likely due to the necrosis/apoptosis pro-
cesses in the tumor tissue or circulating cancer cells.29 In
view of recently published studies, quantitative measurement
of free DNA in serum/plasma might be considered a highly
promising and very cost-effective biomarker for lung cancer
screening and detection. Importantly, elevated amounts of
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circulating free DNA have been observed as early as the
initial stages of lung tumor development.31
Sozzi et al.31 measured circulating plasma DNA using
a simple colorimetric assay and reported that 45% of 84
NSCLC patients exhibited up to 17 times higher levels of
plasma DNA than healthy controls (optimized cutoff, 250
ng/ml). It has been shown that quantification of plasma DNA
with optimally selected cutoff might be a valuable tool to
discriminate patients from healthy individuals. Consequently,
the same research group has applied quantitative real-time
PCR of the human telomerase reverse transcriptase (hTERT)
gene to measure cancer-derived DNA and to discriminate
lung cancer patients from healthy smoking and nonsmoking
controls. Very satisfactory sensitivity (90%) and specificity
TABLE 2. Studies Evaluating Serum or Plasma Markers in Lung Cancer Patients and Controls
Reference Tumor Type Marker s/p Method
Serum/Plasma
PositiveNo. of
Patients
No. of
Controls
%
PositiveNo. %
Fournie et al., 199552 NSCLC/SCLC Total DNA p Nick translation 68 36 53 26 0
Sozzi et al., 200131 NSCLC Total DNA p Colorimetry 84 45 54 43 0
Herrera et al., 200533 NSCLC -Actin p RT qPCR 25 12 48 11 0
Sozzi et al., 200332 NSCLC hTERT p RT qPCR 100 69 69 100 2
Pelosi et al., 200651 NSCLC hTERT mRNA p RT qPCR 34 4 12 10 0
Kopreski et al., 200148 NSCLC 5T4 mRNA s RT-PCR 14 6 43 25 12
Fleischhacker et al., 200149 NSCLC/SCLC Her2/neu mRNA s RT-PCR 18 7 39 12 0
hnRNP B1 mRNA 18 14 78 12 0
Sueoka et al., 200550 NSCLC/SCLC hnRNP B1 mRNA p RT qPCR 44 20 45 25 12
Esteller et al., 199937 NSCLC Methylation p16,
DAPK, GSTpi,
O6MGMT
s MSP 22 12 54 11 0
Bearzatto et al., 200240 NSCLC Methylation p16 p F-MSP 35 12 34 15 0
An et al., 200241 NSCLC Methylation p16 p Seminested MSP 105 77 73 0
Liu et al., 200353 NSCLC/SCLC Methylation p16 p Seminested MSP 50 36 72 0
Usadel et al., 200254 NSCLC Methylation APC s/p RT qPCR 89 42 47 50 0
Ramirez et al., 200338 NSCLC Methylation TMS1,
RASSF1, DAPK
s MSP 50 36 72 0
Fujiwara et al., 200539 NSCLC/SCLC Methylation
MGMT, p16,
RASSF1A,
DAPK, RAR-
s MSP 91 45 49 100a 8
Sozzi et al., 199955 NSCLC MAs (2 markers) p Radio PCR 87 35 40 14 0
Khan et al., 200456 NSCLS/SCLC MAs (3 markers p Radio PCR 86 59 69 120a 42
Bruhn et al., 200057 NSCLC MAs (3 markers) p Radio PCR 27 9 33 10 0
SCLC 16 5 31
Cuda et al., 200058 NSCLC MAs (3 markers) s Silver PCR 17 7 41 31 0
SCLC MAs (3 markers) 11 7 64
Chen et al., 199636 SCLC MAs (3 markers) p Radio PCR 21 15 71 0
Gonzalez et al., 200043 SCLC MAs (3 markers) p F-PCR 16 9 56 0
Sanchez-Cespedes et al.,
199845
NSCLC As (4 markers) s Radio PCR 22 6 28 0
Sozzi et al., 200131 NSCLC MAs (5 markers) p F-PCR 38 9 24 43 0
Bearzatto et al., 200240 NSCLC MAs (5 markers) p F-PCR 34 11 32 0
Beau-Faller et al., 200344 NSCLS/SCLC MAs (12 markers) p F-PCR 20 17 85 20 0
Gonzalez et al., 200043 SCLC TP53 mutation p PCR-SSCP 35 6 17 13 0
Andriani et al., 200446 NSCLC TP53 mutation p Hybridization 26 19 73 0
Bearzatto et al., 200240 NSCLC K-r as mutation s Enriched PCR 35 0 0 0
Ramirez et al., 200338 NSCLC K-ras mutation s Enriched PCR 50 12 24 0
APC, adenomatous polyposis coli; DAPK, death-associated protein kinase; F-MSP, fluorescent MSP; F-PCR, fluorescent polymerase chain reaction; GSTp, glutathione S-transferase;
Her2/neu, human epidermal growth factor receptor 2; hnRNP B1, heterogeneous nuclear ribonucleoprotein B1; hTERT, human telomerase catalytic component; MAs, microsatellite
alterations; MSP, methylation-specific polymerase chain reaction; NSCLC, non-small cell lung cancer; O6MGMT, O6-methylguanine methyltransferase; PCR-SSCP, polymerase chain
reaction–single-strand conformational polymorphism; p, plasma; radio(silver) PCR, polymerase chain reaction with detection of amplification products by autoradiography (silver staining);
RASSF1A, RAS-associated domain family 1A; RT-PCR, reverse-transcriptase polymerase chain reaction; RT qPCR, real-time quantitative polymerase chain reaction; s, serum; SCLC,
small-cell lung cancer; TMS1, target methylation–inducing silencing.
a Control group consisted of patients with nonmalignant pulmonary diseases.
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(86%) have been demonstrated with a positive predictive
value of 90% and negative predictive value of 90%.32 Sixty-
nine of 100 evaluated NSCLC patients and two of 100
controls showed elevated circulating DNA levels, which were
eight times higher in the plasma of patients than controls
(24.3 versus 3.1 ng/ml). The calculated relative risk of lung
cancer was 85 times higher in subjects with a high DNA
concentration. The striking difference in circulating DNA
plasma levels reported in both studies might also be attribut-
able to the sensitivity of the method used because colorimet-
ric assays detect all DNA fragments available in the sample,
whereas quantitative PCR measures only amplifiable DNA
(hTERT).33
Real-time PCR can be regarded as the standard method
currently available for DNA quantification. It allows simul-
taneous amplification and detection of specific DNA se-
quences by monitoring the fluorescence of dyes or probes
introduced into the reaction in proportion to the amount of
product formed. Consequently, real-time PCR is character-
ized by high accuracy, reproducibility, and time-effective-
ness. To validate the method, Gautschi et al.34 evaluated the
impact of several essential factors on the reproducibility of
DNA measurement: blood collection tube brand, DNA con-
centration assessment technique, DNA quantification proce-
dures, and interassay operations. Results have indicated that
the median variation is relatively low (4%, 25%, 20%, and
24%, respectively), allowing comparable and repeatable re-
sults in independent centers.
Additionally, it has been suggested that plasma DNA is
superior to serum-derived material in terms of its diagnostic
value. Plasma, which is less contaminated with DNA of
nontumor origin (serum may contain a variable fraction of
DNA derived from in vivo and in vitro damaged hematopoi-
etic cells), is considered a more reliable source for the
analysis of tumor-specific genetic and epigenetic alterations
in circulating DNA.34
Extrapolating data from ovarian cancer studies, it has
been assumed that a diagnostic panel combining free DNA
assessment, together with analysis of other gene(s) modifica-
tion(s) typical for lung cancer, might prove extremely effi-
cient.35 Subsequently, several studies have clearly demon-
strated that identification of various genetic alterations related
to human lung cancer in the circulating serum/plasma DNA is
feasible.36,37 So-called tumor molecular signatures, markers
characteristic for primary tumor, such as MSI, TP53, and
K-ras mutations, tumor suppressor genes, and DNA repair
gene hypermethylation, have been identified in circulating
DNA, confirming their tumor origin.
The abnormal methylation of four oncogenes (p16,
DAPK, GSTpi, O6MGMT) was first observed by Esteller et
al.37 in the serum DNA from 11 of 22 (50%) NSCLC patients
using the MSP technique. Likewise, Ramirez et al.38 con-
firmed a high frequency of RASSF1A, DAPK, and TMS-1
(34%, 45%, and 35%, respectively) methylated DNA, allow-
ing identification in 72% of 50 NSCLC patients (at least one
methylated gene). They also demonstrated a highly signifi-
cant correlation between the methylation rate in tumor tissue
and serum. Similarly, Fujiwara et al.,39 who analyzed five
markers (MGMT, p16, RASSF1A, DAPK, RAR) in serum
DNA from lung cancer and nonmalignant pulmonary pa-
tients, demonstrated that the methylation ratio of all exam-
ined genes was significantly higher in lung cancer patients
with an overall sensitivity of 49%, 5%, and 1% to 8%,
respectively, in each group.
The implementation of fluorescent primers and laser
detection system (F-MSP technique) further increased (up to
55%) the detection rate of p16 hypermethylation in plasma
DNA samples from NSCLC patients.40 An et al.41 demon-
strated that application of seminested MSP might additionally
enhance the sensitivity of p16 methylation analysis, resulting
in 73.3% positivity in lung cancer patients, a value signifi-
cantly higher than that reported by other studies. Moreover,
the recent technologic innovation of microchip electrophore-
sis offers rapid and accurate analysis of the PCR products
from the methylated p16 gene in plasma DNA, with a
positive rate 26.67% higher than that with slab gel electro-
phoresis, allowing detection in 13 of 48 (27%) lung cancer
patients.42
Plasma DNA samples from lung cancer patients have
also been studied for other biomarkers typically evaluated in
tumor tissue, mainly loss of heterozygosity and allele shifts.
As early as 1996, Chen et al.36 reported the presence of MAs
(three markers) in 15 of 21 (71%) plasma samples from
SCLC patients. Next, Gonzalez et al.43 screened 35 small-cell
lung cancer (SCLC) patients for alterations of three polymor-
phic markers and demonstrated that 56% of 16 available
tumor samples showed molecular changes precisely matching
those observed in plasma DNA. Furthermore, Beau-Faller et
al.44 evaluated 12 microsatellite markers targeting nine dif-
ferent chromosomal regions and showed a sensitivity of 85%
in detecting lung cancer–associated alterations in 17 of 20
plasma DNA samples from NSCLC and SCLC patients.
Importantly, they observed no alterations in plasma or bron-
chial biopsy DNA from 20 control patients.
However, Sanchez-Cespedes et al.45 with four markers
selected, as well as Sozzi et al.31 and Bearzatto et al.40
evaluating five different markers, demonstrated alterations in
only 28%, 24%, and 32% of NSCLC cases, respectively.
Such a divergence between the increased number of markers
and the decreased positive frequency observed might be
attributable to the lack of uniformity in the markers and
specimen selection, the low number of evaluated patients, and
the considerable variety of lung cancer histologic types.
Moreover, the sensitivity of microsatellite PCR assays is
quite low and may vary significantly depending on the
method used for detecting the amplification products. Note
also that differences in the allelic alterations in paired plasma
and tumor DNA samples might be due to the presence of
heterogeneous tumor clones with diverse access to the blood-
stream or to the insufficient tumoral microdissection tech-
nique, with too many normal cells masking the loss of
heterozygosity pattern of tumor cells.
Some studies have also suggested that introducing
different marker sets for SCLC and NSCLC would consid-
erably improve their discrimination rate. Nevertheless, sev-
eral comparable studies that applied uniform marker panels
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(ACTBP 2, UT 762, and AR) had analogous characteristics of
patient groups (age, sex, and stage), used identical DNA
extraction protocols and PCR conditions, and produced dis-
cordant results.36,45 Thus, it should not be forgotten that the
high rate of artifacts unique to PCR of minute quantities, for
example, the phenomenon of allele dropout, appears to be
related not only to the PCR running conditions, but also to the
techniques allowing DNA preparation from single cells (in-
complete cell lysis) and sample handling (pipetting accuracy
and contamination).
Several studies have also evaluated the TP53 and K-ras
mutations in serum or plasma, with quite disappointing re-
sults. In the study by Gonzalez et al.,43 only six of 35 SCLC
patients exhibited a TP53 mutation in their tumor and plasma
DNA samples. Meanwhile, Andriani et al.46 identified p53
genomic mutations in 26 (40.6%) of 64 tumor DNA
(NSCLC) and 19 (73.1%) corresponding plasma samples by
implementing a plaque hybridization assay and direct DNA
sequencing. Ramirez et al.,38 who analyzed the K-ras marker
(codon 12) in tumor and paired serum DNA of 50 resected
NSCLC patients, detected mutations in nine tumors and 12
serum samples; only one patient carried the same mutation in
the tumor and serum. Negative results have also been pub-
lished by Bearzatto et al.,40 who found no K-ras mutation in
the plasma DNA of 35 NSCLC patients, and by Trombino et
al.,47 who observed no difference in the number of K-ras
mutations in the plasma of NSCLC patients and healthy
volunteers. Consequently, the prognostic role of K-ras point
mutations evaluated in the serum DNA of NSCLC patients
needs further confirmation.
Note that a combination of different marker types in
plasma DNA, such as gene mutation, microsatellite instabil-
ity, and DNA quantification, has dramatically increased the
percentage of lung cancer patients identified. The diagnostic
panel of the TP53 mutation and three polymorphic markers
enhanced the sensitivity up to 71% (at least one molecular
change precisely matching that of the primary tumor).43
Similarly, simultaneous evaluation of p16 methylation status,
MAs, and DNA quantification guaranteed an identification
rate of 62% to 80% in NSCLC patients.40 Accordingly,
positive detection of TP53, FHIT, and 3p markers effectively
identified 68.2% (15 of 22) of stage I patients with similar
alterations in the tumor.47
The reviewed reports on the evaluation of biomarkers
in the plasma clearly demonstrate that none of the analyzed
combinations have sufficient sensitivity and specificity for
clinical use. Likewise, diagnostic techniques applied in the
above-mentioned studies differ significantly. Hence, diver-
gent or even contradictory results were presented in several
reports. Thus, standardization of blood sample collection and
DNA assay procedures, as well as larger, better matched
case-control series are critical for the validation of competent
and comparable results.
Apart from the plasma DNA studies, several interesting
reports concerning tumor-related circulating mRNA in the
peripheral blood of lung cancer patients should also be
mentioned. The most promising results have been reported
for thyrosinase (5T4) mRNA (in 43% of lung cancer patients
and 12% of healthy controls) and for the combination of
hnRNP B1 and Her2/neu mRNA markers in serum (all
NSCLC and SCLC patients examined).48,49 Other evaluated
mRNA markers either lacked sensitivity (MAGE-2, PGP, and
TTF-1) or specificity (CK19). Subsequently, hnRNP B1
mRNA and hTERT mRNA markers were assessed and showed
a positive detection ratio in 44.5% and 12% of NSCLC patients,
respectively.50,51 These data demonstrate the necessity for fur-
ther comparative studies on larger groups that will yield more
conclusive results and allow better evaluation of the potential
diagnostic value of circulating RNA testing.
SUMMARY
Recent developments in the genetic diagnostics of lung
cancer promise to provide clinicians with new, efficient
noninvasive tools that are useful for screening and early
detection of lung cancer. Analysis of genetic alterations in
circulating DNA has been particularly noteworthy, as expres-
sion of the biomarkers in plasma corresponds adequately with
their presence in tumors. Importantly, the amount of sample
required is limited and is easily and inexpensively accessible.
However, further detailed validation of respective plasma-de-
rived biomarkers is necessary in large multicenter clinical stud-
ies, with relevant attention paid to the methodologic issues.
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